Screener
Arcutis Biotherapeutics, Inc. ARQT ZORYVE Cream0.3 — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| ZORYVE cream 0.3% | $35,327 | $27,675 | $67,997 | $51,062 |
| ZORYVE foam | 67,377 | 39,212 | 117,004 | 69,452 |
| ZORYVE cream 0.15% | 24,231 | 14,617 | 45,972 | 24,836 |
| ZORYVE cream 0.05% | 2,926 | — | 4,286 | — |
| Total product revenue, net | 129,861 | 81,504 | 235,259 | 145,350 |
| Other revenue | — | — | — | 2,000 |
| Total revenues | $129,861 | $81,504 | $235,259 | $147,350 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s ZORYVE cream0.3 — product revenue, net?
- Arcutis Biotherapeutics, Inc. (ARQT) reported ZORYVE cream0.3 — product revenue, net of $35.33M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s ZORYVE cream0.3 — product revenue, net changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s ZORYVE cream0.3 — product revenue, net increased by 27.6% year-over-year, from $27.68M to $35.33M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s ZORYVE cream0.3 — product revenue, net?
- Over 2 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s ZORYVE cream0.3 — product revenue, net has grown at a 472.9% compound annual growth rate (CAGR), from $3.69M to $121M.
- What does ZORYVE cream0.3 — product revenue, net mean?
- This metric represents the total net sales generated from the specific pharmaceutical product line after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of market adoption, commercial traction, and the revenue-generating capacity of the company's lead dermatological therapeutic. Monitoring this figure helps investors assess the product's growth trajectory and its contribution to the overall commercial success of the company's portfolio.
Ask your AI about Arcutis Biotherapeutics, Inc.'s zoryve cream0.3 — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude